We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Portable Point-of-Care (POC) Device to Monitor Blood Ammonia in Liver Disease Patients

By LabMedica International staff writers
Posted on 15 Apr 2022
Print article
Image: POC device could monitor blood ammonia in liver disease patients (Photo courtesy of Versantis)
Image: POC device could monitor blood ammonia in liver disease patients (Photo courtesy of Versantis)

Increased blood ammonia levels are a common sign of chronic and acute liver diseases and lead to hepatic encephalopathy (HE), which is a serious neurologic condition caused when toxins, including ammonia, that are normally cleared by the liver accumulate in the blood, eventually affecting the brain. Elevated ammonia concentration in the serum and central nervous system (hyperammonemia) is the mainstay for the pathogenesis and treatment of HE. Now, a portable point-of-care (POC) device for blood ammonia monitoring could help meet these challenges.

Versantis AG (Zurich, Switzerland) is developing a prototype POC device named TS-01 based on the polymersome-based ammonia quantification method. TS-01 is a unique point-of-care diagnostic device for at-home measurement of ammonia in blood, the primary cause of HE. The TS-01 assay exclusively licensed by Versantis is based on transmembrane pH-gradient polymersomes that encapsulate a pH-sensitive ratiometric fluorophore. By measuring this fluorescence signal, the ammonia concentration in the sample can be determined. TS-01 has been shown to be accurate across a wider physiological and pathological ammonia concentration range than today’s existing instrumentation and is negligibly impacted by endogenous interferences.

“There is a great unmet medical need for an accurate and user-friendly device to monitor the levels of ammonia in patients with liver disease,” said Dr. Vincent Forster, CSO and co-Founder of Versantis. “Hyperammonemia and its associated neurological manifestations, such as hepatic encephalopathy, affects 30-45% of cirrhotic patients and can lead to coma and death. We believe using a novel portable point-of-care device will allow daily monitoring of ammonia, thereby significantly reducing hospitalizations and fatal outcomes for patients, while also saving time, effort, and expense of health care professionals, supporting caregivers, and family members.”

Related Links:
Versantis AG 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.